Radioligand therapy trial starts vs Alzheimer's disease drug trial starts

In 2025, radioligand therapy trial starts worldwide stood at 79, against 78 for alzheimer's disease drug trial starts.

Change the pair

Compare different indicators

The series

Over time

Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.

Radioligand therapy trial starts and Alzheimer's disease drug trial starts

Unit: count · 12 observations

2 series · one axis
Radioligand therapy trial starts and Alzheimer's disease drug trial starts: GlobalRadioligand therapy trial starts and Alzheimer's disease drug trial starts. 2 indicators on one axis: Radioligand therapy trial starts, Alzheimer's disease drug trial starts. 12 observations from 2020 to 2025, ranging from 31 to 87. Latest values: Radioligand therapy trial starts 79 (2025); Alzheimer's disease drug trial starts 78 (2025). 0 20 40 60 80 100 2020 2021 2022 2023 2024 2025 79 78 Radioligand therapy trial starts Alzheimer's disease drug trial starts
Radioligand therapy trial starts and Alzheimer's disease drug trial starts: GlobalRadioligand therapy trial starts and Alzheimer's disease drug trial starts. 2 indicators on one axis: Radioligand therapy trial starts, Alzheimer's disease drug trial starts. 12 observations from 2020 to 2025, ranging from 31 to 87. Latest values: Radioligand therapy trial starts 79 (2025); Alzheimer's disease drug trial starts 78 (2025). 0 30 60 90 2020 2021 2022 2023 2024 2025 79 78 Radioligand therapy trial starts Alzheimer's disease drug trial starts
Radioligand therapy trial starts and Alzheimer's disease drug trial starts: GlobalRadioligand therapy trial starts and Alzheimer's disease drug trial starts. 2 indicators on one axis: Radioligand therapy trial starts, Alzheimer's disease drug trial starts. 12 observations from 2020 to 2025, ranging from 31 to 87. Latest values: Radioligand therapy trial starts 79 (2025); Alzheimer's disease drug trial starts 78 (2025). 0 30 60 90 2020 2021 2022 2023 2024 2025 79 78 Radioligand therapy trial starts Alzheimer's disease drug trial starts
View the underlying data
Radioligand therapy trial starts and Alzheimer's disease drug trial starts: Global
Indicator Period Type Value
Radioligand therapy trial starts 2025 Actual 79
Radioligand therapy trial starts 2024 Actual 79
Radioligand therapy trial starts 2023 Actual 67
Radioligand therapy trial starts 2022 Actual 50
Radioligand therapy trial starts 2021 Actual 31
Radioligand therapy trial starts 2020 Actual 36
Alzheimer's disease drug trial starts 2025 Actual 78
Alzheimer's disease drug trial starts 2024 Actual 71
Alzheimer's disease drug trial starts 2023 Actual 58
Alzheimer's disease drug trial starts 2022 Actual 81
Alzheimer's disease drug trial starts 2021 Actual 87
Alzheimer's disease drug trial starts 2020 Actual 66
Source: ClinicalTrials.gov · CC BY 4.0 · Radioligand therapy trial starts · Alzheimer's disease drug trial starts

Shared periods

Side by side

6 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.

Period Radioligand therapy trial starts Alzheimer's disease drug trial starts
2020 36 ClinicalTrials.gov 66 ClinicalTrials.gov
2021 31 ClinicalTrials.gov 87 ClinicalTrials.gov
2022 50 ClinicalTrials.gov 81 ClinicalTrials.gov
2023 67 ClinicalTrials.gov 58 ClinicalTrials.gov
2024 79 ClinicalTrials.gov 71 ClinicalTrials.gov
2025 79 ClinicalTrials.gov 78 ClinicalTrials.gov

Provenance

Where these numbers come from

Radioligand therapy trial starts

Count of interventional studies whose interventions name a therapeutic radioisotope (lutetium-177, actinium-225, lead-212, radium-223, terbium, copper-67) or radioligand therapy whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in Global · source organisations: ClinicalTrials.gov

Alzheimer's disease drug trial starts

Count of interventional drug or biologic studies in Alzheimer's disease whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.

6 observations charted in Global · source organisations: ClinicalTrials.gov

Data published under CC BY 4.0. Series A as JSON · Series B as JSON

Keep exploring

Related